Core Insights - Alcon reported revenue of $2.45 billion for Q1 2025, a year-over-year increase of 0.3%, with EPS of $0.73 compared to $0.78 a year ago, missing the Zacks Consensus Estimate of $2.51 billion by -2.32% and EPS estimate by -3.95% [1] Financial Performance - The company's net sales by region included $1.31 billion in international sales, slightly below the $1.39 billion estimate, reflecting a year-over-year increase of 1.5% [4] - In the United States, net sales reached $1.14 billion, exceeding the $1.12 billion estimate [4] - Total Surgical net sales were $1.33 billion, below the $1.38 billion estimate, showing a year-over-year decline of 0.5% [4] - Total Vision Care net sales were $1.12 billion, slightly below the $1.14 billion estimate, with a year-over-year increase of 1.3% [4] Segment Performance - Total Surgical Consumables generated $712 million, compared to the $717.01 million estimate, marking a year-over-year increase of 3.8% [4] - Total Surgical Equipment/Other sales were $199 million, below the $223.04 million estimate, reflecting a year-over-year decline of 9.1% [4] - Total Vision Care Contact Lenses sales were $688 million, slightly below the $693.41 million estimate, with a year-over-year increase of 2.5% [4] - Total Vision Care Ocular Health sales were $432 million, below the $441.87 million estimate, showing a year-over-year decline of 0.7% [4] - Total Surgical Implantables sales were $420 million, below the $435.74 million estimate, reflecting a year-over-year decline of 3% [4] - Other revenues reached $22 million, exceeding the $17.50 million estimate, with a significant year-over-year increase of 46.7% [4] Stock Performance - Alcon's shares returned +4.7% over the past month, compared to the Zacks S&P 500 composite's +9.1% change, with a current Zacks Rank of 3 (Hold), indicating potential performance in line with the broader market [3]

Core Viewpoint - Analysts expect Alcon to report quarterly earnings of $0.76 per share, reflecting a year-over-year decline of 2.6%, with revenues projected at $2.51 billion, an increase of 2.7% from the previous year [1] Earnings Estimates - There have been no revisions in the consensus EPS estimate for the quarter over the last 30 days, indicating stability in analysts' forecasts [1][2] Key Metrics Projections - Analysts estimate 'Net Sales- Total Surgical' to be $1.38 billion, representing a year-over-year increase of 2.8% [3] - The forecast for 'Net Sales- Total Vision Care' is $1.14 billion, indicating a year-over-year change of 2.7% [4] - 'Net Sales- Total Surgical- Consumables' is projected to reach $717.01 million, reflecting a 4.5% increase from the prior year [4] - 'Net Sales- Total Surgical- Equipment/other' is expected to be $223.04 million, showing a 1.8% year-over-year change [4] - 'Net Sales- Total Vision Care- Contact lenses' is anticipated to be $693.41 million, indicating a 3.3% increase from the previous year [5] - 'Net Sales- Total Vision Care- Ocular health' is projected at $441.87 million, reflecting a year-over-year change of 1.6% [5] - 'Net Sales- Total Surgical- Implantables' is expected to reach $435.74 million, indicating a 0.6% increase from the prior year [6] - The consensus for 'Revenues- Other revenues' stands at $17.50 million, reflecting a significant year-over-year increase of 16.7% [6] - 'Net sales by region- International' is projected to be $1.39 billion, indicating a 7.4% increase from the previous year [6] Stock Performance - Alcon shares have increased by 6.8% over the past month, compared to an 11.3% increase in the Zacks S&P 500 composite, with a Zacks Rank of 3 (Hold), suggesting expected performance in line with the overall market [7]